600079 ST人福
已收盘 08-20 15:00:00
资讯
新帖
简况
ST人福:海外业务现已覆盖了欧美成熟市场以及南美、东南亚、中亚、西非、东非等新兴市场
证券之星 · 08-20 16:45
ST人福:海外业务现已覆盖了欧美成熟市场以及南美、东南亚、中亚、西非、东非等新兴市场
ST人福:目前该项目处于研发申报阶段
证券之星 · 08-20 16:45
ST人福:目前该项目处于研发申报阶段
ST人福:公司2026年度向特定对象发行A股股票事项已于2026年8月3日获上海证券交易所受理
证券之星 · 08-20 16:42
ST人福:公司2026年度向特定对象发行A股股票事项已于2026年8月3日获上海证券交易所受理
ST人福(600079.SH):RFUS-188注射液进入II期临床试验研究
智通财经 · 08-20 15:51
ST人福(600079.SH):RFUS-188注射液进入II期临床试验研究
ST人福(600079)新增【AI医疗】概念
证券之星 · 08-06
ST人福(600079)新增【AI医疗】概念
ST人福最新公告:子公司布瑞哌唑片获药品注册证书
证券之星 · 08-06
ST人福最新公告:子公司布瑞哌唑片获药品注册证书
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告》
证券之星 · 08-06
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告》
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告》
证券之星 · 08-05
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告》
ST人福(600079.SH)向特定对象发行A股股票申请获上交所受理
智通财经 · 08-04
ST人福(600079.SH)向特定对象发行A股股票申请获上交所受理
ST人福(600079)披露全资子公司出售资产进展公告,7月28日股价上涨0.98%
证券之星 · 07-28
ST人福(600079)披露全资子公司出售资产进展公告,7月28日股价上涨0.98%
ST人福(600079.SH):HW243040片获得药物临床试验批准通知书
智通财经 · 07-28
ST人福(600079.SH):HW243040片获得药物临床试验批准通知书
ST人福(600079.SH):卡马西平缓释片(Ⅱ)获得药品注册证书
智通财经 · 07-27
ST人福(600079.SH):卡马西平缓释片(Ⅱ)获得药品注册证书
每周股票复盘:ST人福(600079)拟每股派现0.48元
证券之星 · 07-26
每周股票复盘:ST人福(600079)拟每股派现0.48元
ST人福(600079)披露2025年年度权益分派实施公告,7月24日股价下跌1.66%
证券之星 · 07-24
ST人福(600079)披露2025年年度权益分派实施公告,7月24日股价下跌1.66%
ST人福:公司积极关注并探索新技术在药物研发过程中的应用
证券之星 · 07-24
ST人福:公司积极关注并探索新技术在药物研发过程中的应用
ST人福:调整定增定价基准日更好保护中小股东
证券之星 · 07-24
ST人福:调整定增定价基准日更好保护中小股东
ST人福:盐酸他喷他多口服溶液用于缓解中度至重度急性疼痛
证券之星 · 07-24
ST人福:盐酸他喷他多口服溶液用于缓解中度至重度急性疼痛
ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书
智通财经 · 07-24
ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书
ST人福(600079)披露尼达尼布软胶囊获得美国FDA批准文号,7月10日股价上涨0.41%
证券之星 · 07-10
ST人福(600079)披露尼达尼布软胶囊获得美国FDA批准文号,7月10日股价上涨0.41%
ST人福(600079.SH):HW211026软膏进入II期临床试验研究
智通财经 · 07-09
ST人福(600079.SH):HW211026软膏进入II期临床试验研究
公司概况
公司名称:
人福医药集团股份公司
所属行业:
医药制造业
上市日期:
1997-06-06
主营业务:
人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。经过30多年的发展,公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。
发行价格:
5.22
{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"ST人福","latestPrice":17.86,"timestamp":1787209201000,"preClose":18.05,"halted":0,"volume":11124429,"delay":0,"changeRate":-0.0105,"floatShares":1543000000,"shares":1632000000,"eps":1.166,"marketStatus":"已收盘","change":-0.19,"latestTime":"08-20 15:00:00","open":18.04,"high":18.2,"low":17.83,"amount":200000000,"amplitude":0.0205,"askPrice":17.88,"askSize":335,"bidPrice":17.86,"bidSize":67,"shortable":0,"etf":0,"ttmEps":1.166,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":18.05,"symbolType":"stock","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":18.95,"lowLimit":17.15,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":1632225965,"isCdr":false,"pbRate":1.5,"roa":"--","peRate":15.317324,"roe":"3.07%","epsLYR":1.14,"committee":0.489362,"marketValue":29152000000,"turnoverRate":0.0072,"status":1,"floatMarketCap":27561000000},"requestUrl":"/m/hq/s/600079/wiki","defaultTab":"wiki","newsList":[{"id":"2660340785","title":"ST人福:海外业务现已覆盖了欧美成熟市场以及南美、东南亚、中亚、西非、东非等新兴市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2660340785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660340785?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:45","pubTimestamp":1787215512,"startTime":"0","endTime":"0","summary":"如有重大进展,公司将严格按照相关法律法规及时履行信息披露义务。公司坚定实施国际化战略,持续完善覆盖研发、注册、生产、销售的全价值链海外布局,海外业务现已覆盖了欧美成熟市场以及南美、东南亚、中亚、西非、东非等新兴市场,正稳步推进国际注册与销售体系建设。海外业务受市场环境、政策等多重因素影响,敬请投资者关注公司定期报告及公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000029079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0012","BK0028","BK0239","600079","BK0188","BK0096","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660078664","title":"ST人福:目前该项目处于研发申报阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2660078664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660078664?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:45","pubTimestamp":1787215510,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)08月20日在投资者关系平台上答复投资者关心的问题。投资者提问:盐酸胍法辛缓释片申报情况,怎么迟迟没批件ST人福回复:尊敬的投资者,您好!目前该项目处于研发申报阶段,相关工作在正常推进中。医药产品研发周期长、环节多,如有重大事项,公司将严格按照相关法律法规及时履行信息披露义务。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000029077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0185","600079","BK0188","BK0028","BK0012","BK0239","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660027814","title":"ST人福:公司2026年度向特定对象发行A股股票事项已于2026年8月3日获上海证券交易所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2660027814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660027814?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:42","pubTimestamp":1787215327,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)08月20日在投资者关系平台上答复投资者关心的问题。投资者提问:定增被否了吗?迟迟未有消息ST人福回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票事项已于2026年8月3日获上海证券交易所受理,目前处于审核阶段。如有重大进展,公司将根据相关法律法规及时履行信息披露义务。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","399300","BK0185","03130","BK0070","02827","BK0239","BK1147","03188","BK0012","BK0028","07233","BK0188","BK0096","02846","82846","83188","600079","83130"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660404348","title":"ST人福(600079.SH):RFUS-188注射液进入II期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2660404348","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660404348?lang=zh_cn&edition=full","pubTime":"2026-08-20 15:51","pubTimestamp":1787212291,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福 发布公告,公司控股子公司宜昌人福药业有限责任公司近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了RFUS-188注射液II期临床试验登记信息。次要目的:探索RFUS-188注射液重复给药用于术后镇痛的PK/PD特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","IBBQ","PSYK","BMED","BK0096","BK0012","IBBJ","BK0070","BK0239","MDTX","BK0188","BK0028","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631379","title":"ST人福(600079)新增【AI医疗】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657631379?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:30","pubTimestamp":1786019417,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,8月6日ST人福新增概念。ST人福主营业务:药品的研发、生产和销售。ST人福2026年一季报显示,一季度公司主营收入61.01亿元,同比下降0.59%;归母净利润5.88亿元,同比上升8.85%;扣非净利润5.54亿元,同比上升4.24%;负债率39.68%,投资收益2319.8万元,财务费用1.02亿元,毛利率49.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600036798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0188","BK0239","600079","BK0012","BK0070","BK0096","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657132686","title":"ST人福最新公告:子公司布瑞哌唑片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657132686","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657132686?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:41","pubTimestamp":1786005713,"startTime":"0","endTime":"0","summary":"ST人福(600079.SH)公告称,公司控股子公司宜昌人福近日收到国家药监局核准签发的布瑞哌唑片的《药品注册证书》。该药品主要用于治疗成人精神分裂症,获批标志着宜昌人福具备在国内市场销售该产品的资格,将进一步丰富公司产品线。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600027356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0096","BK0185","BK0028","600079","BK0070","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521482","title":"股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657521482?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:42","pubTimestamp":1785951732,"startTime":"0","endTime":"0","summary":"公司公告汇总大信会计师事务所关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告人福医药集团股份公司2025年实现营业收入239.62亿元,归属于母公司所有者的净利润18.55亿元;期末总资产为144.89亿元,净资产为107.16亿元;2025年度拟派发现金红利7.83亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0012","BK0070","600079","BK0096","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657056812","title":"股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657056812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657056812?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:05","pubTimestamp":1785863113,"startTime":"0","endTime":"0","summary":"公司公告汇总大信会计师事务所关于人福医药集团股份公司向特定对象发行股票的财务报告及审计报告人福医药2025年实现营业收入239.62亿元,归属于母公司所有者的净利润18.55亿元;期末总资产144.89亿元,净资产107.16亿元;2025年度拟派发现金红利7.83亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600079","BK0012","BK0070","BK0096","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656536806","title":"ST人福(600079.SH)向特定对象发行A股股票申请获上交所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2656536806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656536806?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:34","pubTimestamp":1785832464,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司于2026年8月3日收到上海证券交易所(简称“上交所”)出具的《关于受理人福医药集团股份公司沪市主板上市公司发行证券申请的通知》,上交所依据相关规定对公司报送的沪市主板上市公司发行证券的募集说明书及相关申请文件进行了核对,认为该项申请文件齐备,符合法定形式,决定予以受理并依法进行审核。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0012","399300","BK0070","600079","159982","BK0096","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654833358","title":"ST人福(600079)披露全资子公司出售资产进展公告,7月28日股价上涨0.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654833358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654833358?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:31","pubTimestamp":1785249074,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘,ST人福报收于17.59元,较前一交易日上涨0.98%,最新总市值为287.11亿元。该股当日开盘17.43元,最高17.69元,最低17.43元,成交额达1.18亿元,换手率为0.44%。近日,ST人福披露《关于全资子公司出售资产的进展公告》。本次交易已获公司第十一届董事会第九次会议审议通过,不构成关联交易和重大资产重组。支付方式为一次性付款,合同自签署之日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600079","BK0239","BK0096","BK0012","BK0070","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654077989","title":"ST人福(600079.SH):HW243040片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654077989","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654077989?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:55","pubTimestamp":1785228941,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福 发布公告,公司全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的HW243040片的《药物临床试验批准通知书》。HW243040片拟用于周围神经病理性疼痛的治疗,是一款口服的小分子新药。HW243040片作为一种非阿片类镇痛药物,其作用靶点基于独特的外周免疫-神经调控机制,从机制上有望规避中枢神经系统相关副作用以及药物依赖与成瘾风险,为患者提供更具安全性的新选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0239","BK0012","BK0070","IBBQ","BK0188","MDTX","PSYK","BMED","BK0185","IBBJ","BK0028","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654090521","title":"ST人福(600079.SH):卡马西平缓释片(Ⅱ)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654090521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654090521?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:33","pubTimestamp":1785137630,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”,公司持有其80%的股权)近日收到国家药品监督管理局核准签发的卡马西平缓释片(Ⅱ)的《药品注册证书》。卡马西平缓释片(Ⅱ)主要用于治疗癫痫,包括部分发作、原发或继发性全身强直-阵挛发作及混合型发作;缓解三叉神经痛,包括由于多发性硬化症引起的三叉神经痛、原发性三叉神经痛及原发性舌咽神经痛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ST人福(600079.SH):卡马西平缓释片(Ⅱ)获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0096","BK0188","BK0070","BK0239","BK0185","600079","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654284052","title":"每周股票复盘:ST人福(600079)拟每股派现0.48元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654284052","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654284052?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:47","pubTimestamp":1785001631,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,ST人福报收于17.19元,较上周的17.45元下跌1.49%。本周,ST人福7月20日盘中最高价报17.81元。本周关注点公司公告汇总:ST人福拟每股派发现金红利0.48元(含税)。公司公告汇总人福医药集团股份公司2025年年度权益分派实施公告:每股派发现金红利0.48元(含税),股权登记日为2026年7月31日,除权(息)日为2026年8月3日,现金红利发放日为2026年8月3日。本次利润分配以公司总股本1,632,225,965股为基数,共派发现金红利783,468,463.20元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0096","BK0185","BK0028","600079","BK0070","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653038182","title":"ST人福(600079)披露2025年年度权益分派实施公告,7月24日股价下跌1.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653038182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653038182?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:15","pubTimestamp":1784902524,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,ST人福报收于17.19元,较前一交易日下跌1.66%,最新总市值为280.58亿元。该股当日开盘17.4元,最高17.48元,最低17.19元,成交额达1.81亿元,换手率为0.68%。公司近日披露《2025年年度权益分派实施公告》:每股派发现金红利0.48元(含税),股权登记日为2026年7月31日,除权(息)日为2026年8月3日,现金红利发放日为2026年8月3日。本次利润分配以公司总股本1,632,225,965股为基数,共派发现金红利783,468,463.20元。部分股东红利由公司自行发放。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0012","600079","BK0188","BK0239","BK0070","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653003587","title":"ST人福:公司积极关注并探索新技术在药物研发过程中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2653003587","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653003587?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:39","pubTimestamp":1784882360,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问:公司有Ai制药布局吗ST人福回复:尊敬的投资者,您好!公司积极关注并探索新技术在药物研发过程中的应用,相关布局及应用情况请查阅公司2025年年度报告“管理层讨论与分析”部分。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600079","BK0070","BK0028","BK0185","BK0239","BK0096","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700317","title":"ST人福:调整定增定价基准日更好保护中小股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700317?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:39","pubTimestamp":1784882356,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福07月24日在投资者关系平台上答复投资者关心的问题。公司本次调整的是定增定价基准日,即将定价基准日调整为“发行期首日”,调整后的定价更加贴近市场公允价格,遵循了市场化原则,从机制上能更好地保护中小股东。公司始终秉持公平公正原则,切实维护广大投资者特别是中小股东的合法权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0239","BK0185","BK0070","BK0028","BK0188","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653707127","title":"ST人福:盐酸他喷他多口服溶液用于缓解中度至重度急性疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2653707127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653707127?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:33","pubTimestamp":1784881996,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福07月24日在投资者关系平台上答复投资者关心的问题。盐酸他喷他多口服溶液主要用于缓解体重超过16kg的2岁以上儿童和成人的中度至重度急性疼痛,目前尚未在国内上市,该产品能满足差异化临床需求,进一步丰富公司镇痛产品梯队。目前该项目尚处于临床试验阶段,未来销售具有不确定性,敬请注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0012","BK0028","BK0239","BK0070","BK0188","BK0185","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653702299","title":"ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653702299","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653702299?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:00","pubTimestamp":1784880020,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福 发布公告,公司全资子公司人福普克药业(武汉)有限公司近日收到国家药品监督管理局核准签发的酒石酸长春瑞滨软胶囊的《药品注册证书》。据悉,酒石酸长春瑞滨软胶囊被批准用于不可手术切除的局部晚期或转移性非小细胞肺癌,和转移性乳腺癌的单药或联合化疗。武汉普克于2024年10月向国家药品监督管理局提交了酒石酸长春瑞滨软胶囊的上市许可申请并获得受理,截至目前,该项目累计研发投入约为1200万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ST人福(600079.SH)子公司酒石酸长春瑞滨软胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0188","BK0239","BK0070","BK0096","600079","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650351031","title":"ST人福(600079)披露尼达尼布软胶囊获得美国FDA批准文号,7月10日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650351031","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650351031?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:14","pubTimestamp":1783692862,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,ST人福报收于17.33元,较前一交易日上涨0.41%,最新总市值为282.86亿元。近日,人福医药集团股份公司全资子公司人福普克药业(武汉)有限公司收到美国食品药品监督管理局关于尼达尼布软胶囊的批准文号,ANDA批件号为218472,规格为100 mg和150 mg,适用于治疗特发性肺纤维化和具有进行性表型的慢性纤维化性间质性肺疾病。根据IQVIA数据,2025年1-9月该药品在美国销售额约为28亿美元。此次获批将有助于公司拓展美国仿制药市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0096","BK0070","600079","BK0188","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650447679","title":"ST人福(600079.SH):HW211026软膏进入II期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2650447679","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650447679?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:58","pubTimestamp":1783583899,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司全资子公司湖北生物医药产业技术研究院有限公司(简称“研究院有限公司”)近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了HW211026软膏II期临床试验登记信息。试验名称:一项评价HW211026软膏治疗光线性角化病的有效性和安全性的多中心、开放标签、给药方案探索II期临床研究;试验目的:评估HW211026软膏治疗光线性角化病的有效性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0188","BMED","BK0096","BK0070","600079","BK0239","IBBQ","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787267584973,"stockEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":0.0481},{"period":"3month","weight":0.0264},{"period":"6month","weight":-0.0442},{"period":"1year","weight":-0.1177},{"period":"ytd","weight":0.0133}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"人福医药集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"80842人(较上一季度减少3.87%)","perCapita":"19088股","listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","registeredCapital":"163222万元","survey":" 人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。经过30多年的发展,公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。","listedPrice":5.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST人福,600079,ST人福股票,ST人福股票老虎,ST人福股票老虎国际,ST人福行情,ST人福股票行情,ST人福股价,ST人福股市,ST人福股票价格,ST人福股票交易,ST人福股票购买,ST人福股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}